Wall Street analysts predict that Atossa Genetics Inc (NASDAQ:ATOS) will post ($0.48) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Atossa Genetics’ earnings. Atossa Genetics posted earnings per share of ($2.04) during the same quarter last year, which indicates a positive year over year growth rate of 76.5%. The business is expected to report its next earnings results on Tuesday, November 13th.
On average, analysts expect that Atossa Genetics will report full year earnings of ($4.19) per share for the current financial year, with EPS estimates ranging from ($4.29) to ($4.08). For the next financial year, analysts expect that the company will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.57) to ($1.81). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atossa Genetics.
Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Monday, August 13th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($0.37) by ($2.53).
Several equities research analysts recently commented on the company. Maxim Group reiterated a “$2.47” rating and set a $10.00 target price on shares of Atossa Genetics in a report on Wednesday, July 18th. ValuEngine upgraded Atossa Genetics from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th.
Shares of NASDAQ:ATOS traded up $0.08 during mid-day trading on Friday, hitting $1.66. 270,255 shares of the company traded hands, compared to its average volume of 330,973. Atossa Genetics has a 52-week low of $1.41 and a 52-week high of $19.08.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Featured Article: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.